Pharvaris (PHVS) News Today

Pharvaris N.V. (NASDAQ: PHVS) shares have edged lower despite a generally favorable news flow, as investors weigh strong clinical results and higher analyst targets against insider selling and the company’s remaining regulatory and commercial risks.

• Positive Sentiment: Analysts continued to support Pharvaris after positive Phase 3 data for extended-release deucrictibant in the CHAPTER-3 prophylaxis trial. The drug met its primary and secondary efficacy endpoints, strengthening the case for regulatory filings expected to begin in the first half of 2027.
• Positive Sentiment: RBC Capital reaffirmed its Buy/Outperform view and raised its price target to $62 from $52, citing the potential for deucrictibant XR to capture share in the hereditary angioedema market. RBC Capital rating
• Positive Sentiment: Citizens JMP increased its target to $79 from $75 and maintained a Market Outperform rating. HC Wainwright reiterated Buy with a $60 target, while Wedbush maintained Outperform. These actions reflect growing analyst confidence following Pharvaris’ Phase 3 progress.
• Positive Sentiment: Commentary highlighted Pharvaris’ potential to offer oral therapies for both on-demand treatment and prevention of hereditary angioedema attacks, which could improve its competitive positioning. Pharvaris HAE market opportunity
• Neutral Sentiment: The bullish outlook remains dependent on regulatory approval, successful commercialization and competition in the HAE market. Pharvaris is still a clinical-stage biotechnology company, and RBC continues to classify the stock as speculative.
• Negative Sentiment: President Peng Lu sold 15,000 shares for approximately $610,200, reducing his direct ownership by 18.71%. The sale may create a modest sentiment overhang, although it does not alter the company’s clinical results.